AIM: To investigate the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in gastric carcinoma and its clinical significance and to explore its relationship with cell proliferation. METHODS: Expressions of IGFBP-2 and Ki-67 in 118 cases of gastric carcinoma and 40 cases of normal gastric mucosa were detected by EnVision immunohistochemical technique. RESULTS: Expression of IGFBP-2 in gastric carcinoma was higher than that in normal gastric mucosa (P < 0.01). There was no difference between high- and low-grade gastric carcinoma (P > 0.05). Expression of IGFBP-2 in advanced gastric carcinoma was higher than that in early gastric carcinoma (P < 0.05). Expression of IGFBP-2 in gastric carcinoma with lymph node metastasis was higher than that without lymph node metastasis (P < 0.01). IGFBP-2 expression was a positively related to the clinical stage of gastric carcinoma (P < 0.01). There was a positive correlation between IGFBP-2 and Ki-67 (P < 0.05). CONCLUSION: IGFBP-2 may be involved in carcino-genesis and progression of gastric carcinoma by promoting cell proliferation.
AIM: To investigate the expression of insulin-like growth factor binding protein-2 (IGFBP-2) in gastric carcinoma and its clinical significance and to explore its relationship with cell proliferation. METHODS: Expressions of IGFBP-2 and Ki-67 in 118 cases of gastric carcinoma and 40 cases of normal gastric mucosa were detected by EnVision immunohistochemical technique. RESULTS: Expression of IGFBP-2 in gastric carcinoma was higher than that in normal gastric mucosa (P < 0.01). There was no difference between high- and low-grade gastric carcinoma (P > 0.05). Expression of IGFBP-2 in advanced gastric carcinoma was higher than that in early gastric carcinoma (P < 0.05). Expression of IGFBP-2 in gastric carcinoma with lymph node metastasis was higher than that without lymph node metastasis (P < 0.01). IGFBP-2 expression was a positively related to the clinical stage of gastric carcinoma (P < 0.01). There was a positive correlation between IGFBP-2 and Ki-67 (P < 0.05). CONCLUSION:IGFBP-2 may be involved in carcino-genesis and progression of gastric carcinoma by promoting cell proliferation.
Authors: A Hoeflich; O Fettscher; H Lahm; W F Blum; H J Kolb; D Engelhardt; E Wolf; M M Weber Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: A G Renehan; J E Painter; D O'Halloran; W S Atkin; C S Potten; S T O'Dwyer; S M Shalet Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: Michael G Moore; Lawrence A Wetterau; Malik J Francis; Donna M Peehl; Pinchas Cohen Journal: Int J Cancer Date: 2003-05-20 Impact factor: 7.396
Authors: A Hoeflich; M Wu; S Mohan; J Föll; R Wanke; T Froehlich; G J Arnold; H Lahm; H J Kolb; E Wolf Journal: Endocrinology Date: 1999-12 Impact factor: 4.736
Authors: Yashwanth Subbannayya; Sartaj Ahmad Mir; Santosh Renuse; Srikanth S Manda; Sneha M Pinto; Vinuth N Puttamallesh; Hitendra Singh Solanki; H C Manju; Nazia Syed; Rakesh Sharma; Rita Christopher; M Vijayakumar; K V Veerendra Kumar; T S Keshava Prasad; Girija Ramaswamy; Rekha V Kumar; Aditi Chatterjee; Akhilesh Pandey; Harsha Gowda Journal: J Proteomics Date: 2015-05-05 Impact factor: 4.044